Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease
Atrogi’s breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic disease First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential in obesity, diabetes, and age-related muscle loss ATR-258 is set to enter Phase 2 trials […]